US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.62

-0.1700-4.49%

Post-market: 3.680.0600+1.66%19:39 EDT

Volume:515.38K

Turnover:1.87M

Market Cap:113.27M

PE:-0.88

High:3.72

Open:3.72

Low:3.58

Close:3.79

52wk High:49.25

52wk Low:3.46

Shares:31.29M

Float Shares:18.39M

Volume Ratio:0.63

T/O Rate:2.80%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.1300

EPS(LYR):-2.8503

ROE:-59.21%

ROA:-37.36%

PB:0.52

PE(LYR):-1.27

Loading ...

Overview Company News Filings

Qyuns Therapeutics' Oturkibart Shows Sustained Efficacy in Phase III Trial

MT Newswires Live

Addex Therapeutics Brings Back Veteran Chemist to Lead Pharmaceutical Development as Pipeline Enters New Phase

Press Release: Addex Therapeutics Announces Executive Management Changes

Nexalis Therapeutics Appoints Non-Executive Chairman

MT Newswires Live

Major Investor Quietly Boosts Stake in Grace Therapeutics

Qyuns Therapeutics’ Oturkibart Shows Strong Phase III PN Data at EADV 2026

Pelthos Therapeutics Shareholders Back Directors and Equity Plan

Akari Therapeutics Enhances CEO Compensation, Equity Incentives

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

Summit Therapeutics is Maintained at Equal-Weight by Barclays

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

Akari Therapeutics expands IP portfolio with PCT filing for ADC payload

Monte Rosa Therapeutics Sees Positive Trial Results for Cardiovascular Disease Treatment

Whitehawk Therapeutics presents real-world analyses of MUC16 in ovarian cancer

Whitehawk Therapeutics Price Target Announced at $9.00/Share by Stifel

Press Release: HLS Therapeutics Announces Board of Directors Changes

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target

MT Newswires Live

Stifel Initiates Whitehawk Therapeutics at Buy With $9 Price Target

MT Newswires Live

JPMorgan Initiates Spyre Therapeutics at Overweight With $110 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/LENZ/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":3.62,"timestamp":1791403200000,"preClose":3.79,"halted":0,"volume":515377,"hourTrading":{"tag":"盘后","latestPrice":3.68,"preClose":3.62,"latestTime":"19:39 EDT","volume":19878,"amount":71988.26,"timestamp":1791416340186,"change":0.06,"changeRate":0.016575,"amplitude":0.024862},"delay":0,"changeRate":-0.044854881266490745,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"Closed","change":-0.17,"latestTime":"10-07 16:00:00 EDT","open":3.72,"high":3.72,"low":3.58,"amount":1871693.104769,"amplitude":0.036939,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791446400000},"marketStatusCode":5,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":3.79,"preHourTrading":{"tag":"盘前","latestPrice":3.7003,"preClose":3.79,"latestTime":"09:24 EDT","volume":96,"amount":356.7211968,"timestamp":1791379482491,"change":-0.0897,"changeRate":-0.023668,"amplitude":0.021108},"postHourTrading":{"tag":"盘后","latestPrice":3.68,"preClose":3.62,"latestTime":"19:39 EDT","volume":19878,"amount":71988.26,"timestamp":1791416340186,"change":0.06,"changeRate":0.016575,"amplitude":0.024862},"volumeRatio":0.626635,"impliedVol":1.7514,"impliedVolPercentile":0.7888},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":18393300,"roa":"-37.36%","roe":"-59.21%","lyrEps":-2.850329,"volumeRatio":0.626635,"shares":31289969,"dividePrice":0,"high":3.72,"amplitude":0.036939,"preClose":3.79,"low":3.58,"week52Low":3.455,"pbRate":"0.52","psRate":"5.27","week52High":49.25,"institutionHeld":0,"latestPrice":3.62,"eps":-4.13,"divideRate":0,"volume":515377,"delay":0,"ttmEps":-4.13,"open":3.72,"prevYearClose":16,"prevWeekClose":3.58,"prevMonthClose":3.84,"prevQuarterClose":3.84,"fiveDayClose":3.84,"twentyDayClose":4.91,"sixtyDayClose":4.93},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LENZ","fiscalQuarterEnding":"2026/06","expectedEps":-1.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-1.02},{"market":"US","date":"2026-05-11","symbol":"LENZ","fiscalQuarterEnding":"2026/03","expectedEps":-1.1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.2857,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-10-06","current":-0.876513,"percent":0.998371,"low":-26.69966,"twenty":-16.204278,"median":-9.56506,"eighty":-3.689515,"high":-0.892723,"avg":-10.241723,"sd":6.312022,"marketCap":112799031},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282},{"date":"2026-04-02","current":-3.569637,"twenty":-16.958959,"median":-11.220775,"eighty":-7.447644,"marketCap":293163583},{"date":"2026-04-10","current":-3.54673,"twenty":-16.933679,"median":-11.193196,"eighty":-7.269441,"marketCap":291282320},{"date":"2026-04-17","current":-3.680353,"twenty":-16.916201,"median":-11.141188,"eighty":-7.181235,"marketCap":302256358},{"date":"2026-04-24","current":-3.493281,"twenty":-16.878888,"median":-11.077981,"eighty":-6.952736,"marketCap":286892705},{"date":"2026-05-01","current":-3.428379,"twenty":-16.817122,"median":-11.044571,"eighty":-6.825202,"marketCap":281562458},{"date":"2026-05-08","current":-3.710895,"twenty":-16.761494,"median":-10.861657,"eighty":-6.578636,"marketCap":304764709},{"date":"2026-05-15","current":-2.097082,"twenty":-16.730518,"median":-10.778852,"eighty":-6.457565,"marketCap":228573532},{"date":"2026-05-22","current":-2.163245,"twenty":-16.709792,"median":-10.723495,"eighty":-6.429023,"marketCap":235785042},{"date":"2026-05-29","current":-2.298448,"twenty":-16.694346,"median":-10.694071,"eighty":-6.404339,"marketCap":250521608},{"date":"2026-06-05","current":-2.071192,"twenty":-16.632408,"median":-10.560046,"eighty":-6.370576,"marketCap":225751636},{"date":"2026-06-12","current":-1.869826,"twenty":-16.608825,"median":-10.439663,"eighty":-6.329861,"marketCap":203803561},{"date":"2026-06-18","current":-1.8238,"twenty":-16.599392,"median":-10.388191,"eighty":-6.238545,"marketCap":198786857},{"date":"2026-06-26","current":-1.585037,"twenty":-16.591349,"median":-10.356288,"eighty":-6.201347,"marketCap":172762710},{"date":"2026-07-02","current":-1.665584,"twenty":-16.562409,"median":-10.323331,"eighty":-6.136275,"marketCap":181541941},{"date":"2026-07-10","current":-1.665584,"twenty":-16.458857,"median":-10.297741,"eighty":-6.098214,"marketCap":181541941},{"date":"2026-07-17","current":-1.403808,"twenty":-16.42504,"median":-10.207556,"eighty":-5.994366,"marketCap":153009442},{"date":"2026-07-24","current":-1.452711,"twenty":-16.399781,"median":-10.175633,"eighty":-5.904593,"marketCap":158339689},{"date":"2026-07-31","current":-1.656954,"twenty":-16.359791,"median":-10.130408,"eighty":-5.831073,"marketCap":180601309},{"date":"2026-08-07","current":-1.501614,"twenty":-16.336075,"median":-10.052902,"eighty":-5.780516,"marketCap":163669936},{"date":"2026-08-14","current":-1.147074,"twenty":-16.332656,"median":-9.910465,"eighty":-5.64279,"marketCap":144533577},{"date":"2026-08-21","current":-1.162036,"twenty":-16.31728,"median":-9.875604,"eighty":-5.484249,"marketCap":146418798},{"date":"2026-08-28","current":-1.19944,"twenty":-16.297238,"median":-9.783769,"eighty":-5.425546,"marketCap":151131849},{"date":"2026-09-04","current":-1.453791,"twenty":-16.251993,"median":-9.763078,"eighty":-5.336455,"marketCap":183180599},{"date":"2026-09-11","current":-1.176997,"twenty":-16.223282,"median":-9.734689,"eighty":-5.236314,"marketCap":148304018},{"date":"2026-09-18","current":-1.029873,"twenty":-16.218091,"median":-9.676907,"eighty":-3.875061,"marketCap":129766016},{"date":"2026-09-25","current":-0.927633,"twenty":-16.212803,"median":-9.639455,"eighty":-3.772744,"marketCap":116883675},{"date":"2026-10-02","current":-0.945089,"twenty":-16.204574,"median":-9.574004,"eighty":-3.700206,"marketCap":119083099},{"date":"2026-10-06","current":-0.895216,"twenty":-16.204278,"median":-9.56506,"eighty":-3.689515,"marketCap":112799031}],"updateTime":1791383377088},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672679263","title":"Qyuns Therapeutics' Oturkibart Shows Sustained Efficacy in Phase III Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2672679263","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672679263?lang=en_us&edition=fundamental","pubTime":"2026-10-02 14:18","pubTimestamp":1790921909,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  reported sustained symptom improvements in a Phase III study of its Oturkibart treatment for adults with moderate-to-severe prurigo nodularis, according to a Friday exchange filing.At Week 24, 74.5% of Oturkibart patients saw reduced itching and 34.7% achieved clear or almost clear skin, compared with 29.0% and 11.1% for the placebo group, respectively. By Week 52, those efficacy rates climbed to 95.5% and 66.9% among patients continuing the treatment.The drug's safety profile was similar to the placebo, with no new long-term risks identified.Shares of the biopharmaceutical firm fell nearly 1% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02509","LENZ","BK1161","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672794954","title":"Addex Therapeutics Brings Back Veteran Chemist to Lead Pharmaceutical Development as Pipeline Enters New Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2672794954","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672794954?lang=en_us&edition=fundamental","pubTime":"2026-10-02 13:32","pubTimestamp":1790919144,"startTime":"0","endTime":"0","summary":"Addex Therapeutics ( ($CH:ADXN) ) has shared an update. Addex Therapeutics has appointed veteran medicinal chemist Jean‑Philippe Rocher as Head of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/addex-therapeutics-brings-back-veteran-chemist-to-lead-pharmaceutical-development-as-pipeline-enters-new-phase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/addex-therapeutics-brings-back-veteran-chemist-to-lead-pharmaceutical-development-as-pipeline-enters-new-phase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","DBB","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672079179","title":"Press Release: Addex Therapeutics Announces Executive Management Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2672079179","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672079179?lang=en_us&edition=fundamental","pubTime":"2026-10-02 13:00","pubTimestamp":1790917200,"startTime":"0","endTime":"0","summary":"-- Jean-Philippe Rocher Appointed Head of Pharmaceutical Development","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4007","BK4539","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672791441","title":"Nexalis Therapeutics Appoints Non-Executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2672791441","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672791441?lang=en_us&edition=fundamental","pubTime":"2026-10-02 12:55","pubTimestamp":1790916912,"startTime":"0","endTime":"0","summary":"Nexalis Therapeutics  appointed Niv Dagan to succeed Sean Williams as non-executive chairman, effective Friday, according to a same-day filing with the Australian bourse.Williams, who has served in the role since July 2021, is resigning to focus on other business commitments and family matters, per the filing.Dagan is the founder and executive director of boutique investment firm Peak Asset Management, the clinical-stage drug development company said. He is also currently the non-executive chairman of Spenda .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7043","SPX.AU","BK7096","BK4539","BK7007","NX1.AU","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672796895","title":"Major Investor Quietly Boosts Stake in Grace Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2672796895","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672796895?lang=en_us&edition=fundamental","pubTime":"2026-10-02 10:03","pubTimestamp":1790906595,"startTime":"0","endTime":"0","summary":"New insider activity at Grace Therapeutics ( ($GRCE) ) has taken place on October 1, 2026. Significant shareholder Opaleye Management Inc. has incr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-boosts-stake-in-grace-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-boosts-stake-in-grace-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672679805","title":"Qyuns Therapeutics’ Oturkibart Shows Strong Phase III PN Data at EADV 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672679805","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672679805?lang=en_us&edition=fundamental","pubTime":"2026-10-02 08:07","pubTimestamp":1790899644,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. Class H ( ($HK:2509) ) has provided an update. Qyuns Therapeutics reported that results from its China Phase III trial...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/qyuns-therapeutics-oturkibart-shows-strong-phase-iii-pn-data-at-eadv-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/qyuns-therapeutics-oturkibart-shows-strong-phase-iii-pn-data-at-eadv-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672677617","title":"Pelthos Therapeutics Shareholders Back Directors and Equity Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2672677617","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672677617?lang=en_us&edition=fundamental","pubTime":"2026-10-02 05:52","pubTimestamp":1790891541,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics ( ($PTHS) ) just unveiled an announcement. On September 29, 2026, Pelthos Therapeutics held its 2026 Annual Meeting of Stockho...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pelthos-therapeutics-shareholders-back-directors-and-equity-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pelthos-therapeutics-shareholders-back-directors-and-equity-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","REZ","BK4588","BK4007","LENZ","BK4215","BK4585","EQR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672767433","title":"Akari Therapeutics Enhances CEO Compensation, Equity Incentives","url":"https://stock-news.laohu8.com/highlight/detail?id=2672767433","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672767433?lang=en_us&edition=fundamental","pubTime":"2026-10-02 05:20","pubTimestamp":1790889651,"startTime":"0","endTime":"0","summary":"An announcement from Akari Therapeutics ( ($AKTX) ) is now available. On September 29, 2026, Akari Therapeutics amended its chief executive officer...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/akari-therapeutics-enhances-ceo-compensation-equity-incentives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/akari-therapeutics-enhances-ceo-compensation-equity-incentives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQR","LENZ","BK4007","BK4585","BK4539","BK4139","BK4215","REZ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672764016","title":"Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672764016","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672764016?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:05","pubTimestamp":1790885100,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., Oct.  01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3373386/0/en/mineralys-therapeutics-announces-presentation-of-lorundrostat-data-at-american-heart-association-hypertension-scientific-sessions-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4117","AFG","MEDX","GDOC","NVIB","BK4007","IDNA","BK4539","BK4107","BK4139","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672757170","title":"Summit Therapeutics is Maintained at Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2672757170","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672757170?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:03","pubTimestamp":1790859780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SMMT/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","LENZ","LU2488822045.USD","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672750840","title":"Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672750840","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672750840?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:01","pubTimestamp":1790859660,"startTime":"0","endTime":"0","summary":"Application represents an important step in supporting reimbursement  Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct.  01, 2026 (GLOBE NEWSWIRE)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372980/0/en/outlook-therapeutics-submits-hcpcs-level-ii-application-to-cms-for-permanent-j-code-for-lytenava-bevacizumab-vikg.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930730.SGD","LU0672654240.SGD","00867","AMDU","AIQ","SOXX","AMDY","AMDS","AMDL","GAMR","AIS","BAI","FAI","AMYY","LU2355687059.USD","AMDG","CNAV","AMUU","SMHX","LU2637428348.USD","QQQA","ILDR","ARTY","TTEQ","SGXZ99366536.SGD","XNTK","PSI","SAMD0main","BK4573","TEK","AMDC","LEGR","WISE","WUGI","USXF","AMDW","DAMD","SOXY","AMDD","SMH","TRFK","CHPS","IETC","CHAT","LENZ","LU2417539215.USD","LU0274383776.USD","AMD","FTXL","CMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672752032","title":"Akari Therapeutics expands IP portfolio with PCT filing for ADC payload","url":"https://stock-news.laohu8.com/highlight/detail?id=2672752032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672752032?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:36","pubTimestamp":1790858214,"startTime":"0","endTime":"0","summary":"Akari Therapeutics (AKTX) announced the filing of PCT/US2026/45955, expanding the Company’s intellectual property portfolio around its novel splici...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/akari-therapeutics-expands-ip-portfolio-with-pct-filing-for-adc-payload-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/akari-therapeutics-expands-ip-portfolio-with-pct-filing-for-adc-payload-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NXTI","AKTX","BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672521387","title":"Monte Rosa Therapeutics Sees Positive Trial Results for Cardiovascular Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2672521387","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672521387?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:25","pubTimestamp":1790857500,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics said it saw positive data from a phase 1 study evaluating MRT-8102, which is being developed to treat inflammatory conditions in patients with elevated risk of cardiovascular disease.The company said Thursday the drug, a molecular glue degrader, successfully targeted and degraded NEK7, a type of protein that drives inflammatory conditions, with a median reduction of about 80% to 90% observed across all three dose levels in the study.Both drivers of plaque growth and progression and systemic inflammatory biomarkers were substantially reduced following MRT-8102 administration at all three dose levels to levels comparable with baseline values from healthy volunteers, the company said.The company said the results are encouraging and support the continued development of MRT-8102 in cardiovascular disease and other indications. The company said it expects to initiate multiple Phase 2 studies of MRT-8102 in indications with high unmet need, including stable coronary ar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4007","BK4082","CSII","GLUE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672975265","title":"Whitehawk Therapeutics presents real-world analyses of MUC16 in ovarian cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2672975265","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672975265?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:15","pubTimestamp":1790856950,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics (WHWK) announced the presentation of two real-world analyses supporting mucin 16 as a durable therapeutic target and potenti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/whitehawk-therapeutics-presents-real-world-analyses-of-muc16-in-ovarian-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/whitehawk-therapeutics-presents-real-world-analyses-of-muc16-in-ovarian-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WHWK","BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672751611","title":"Whitehawk Therapeutics Price Target Announced at $9.00/Share by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2672751611","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672751611?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:13","pubTimestamp":1790853180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/WHWK/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672751314","title":"Press Release: HLS Therapeutics Announces Board of Directors Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2672751314","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672751314?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:00","pubTimestamp":1790852400,"startTime":"0","endTime":"0","summary":"TORONTO, Oct. 1, 2026 /CNW/ -- HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Direc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672475181","title":"Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2672475181","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672475181?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:00","pubTimestamp":1790852400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372716/24675/en/fate-therapeutics-to-participate-in-upcoming-fourth-quarter-2026-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4007","FATE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672040756","title":"HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2672040756","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672040756?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:31","pubTimestamp":1790850697,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) has an average rating of buy and mean price target of $28.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672680756","title":"Stifel Initiates Whitehawk Therapeutics at Buy With $9 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2672680756","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672680756?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:06","pubTimestamp":1790849196,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics (WHWK) has an average rating of overweight and mean price target of $7.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672755763","title":"JPMorgan Initiates Spyre Therapeutics at Overweight With $110 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2672755763","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672755763?lang=en_us&edition=fundamental","pubTime":"2026-10-01 17:46","pubTimestamp":1790847964,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) has an average rating of buy and mean price target of $121, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","PGF"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}